Telix Pharma
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Telix Reports Second Quarter 2022 Financial Results 2022-07-21 08:34
ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment 2022-07-11 08:26
Kevin Richardson appointed as CEO, Telix Americas 2022-07-11 08:13
Telix and Invicro Advance AI Partnership 2022-06-14 19:00
Telix and Invicro Advance AI Partnership 2022-06-14 14:21
Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network 2022-06-13 19:11
Telix and RefleXion Expand Partnership for Prostate Cancer Treatment 2022-06-10 19:00
Telix to Present at Jefferies Healthcare Conference 2022-06-07 19:00
Telix Showcasing Innovation in Theranostics at SNMMI 2022-06-07 05:00
Illuccix® Granted Transitional Pass-Through Payment Status 2022-05-31 19:00
Illuccix® Reimbursement Milestone and Launch Updates: Pass-Through Status Granted in the U.S. 2022-05-30 08:02
First Patient Dosed in Phase II Renal Cancer Theranostics Study 2022-05-05 05:00
Telix Further Strengthens European Distribution Network for Illuccix 2022-04-22 07:10
First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent 2022-04-14 19:00
ProstACT Update: TARGET Study Ethics Approval 2022-04-12 07:47
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab 2022-04-11 06:51
PSMA-PET Imaging to be Funded through Medicare in Australia from July 2022 2022-04-06 12:47
Telix, GMS and Monash Awarded $23M Federal Government Funding as part of $71M Australian Precision Medicine Enterprise (APME) Project 2022-04-04 09:13
Commercial Launch: Illuccix® Now Available to Order in the United States 2022-04-04 07:06
Change of Composition of the Telix Board of Directors 2022-03-31 07:11
1 2 3 4 5 6